ENZ vs. PSNL, XGN, DMTK, PMD, BDSX, AMIX, RPHM, SRTS, ICCM, and KRON
Should you be buying Enzo Biochem stock or one of its competitors? The main competitors of Enzo Biochem include Personalis (PSNL), Exagen (XGN), DermTech (DMTK), Psychemedics (PMD), Biodesix (BDSX), Autonomix Medical (AMIX), Reneo Pharmaceuticals (RPHM), Sensus Healthcare (SRTS), IceCure Medical (ICCM), and Kronos Bio (KRON). These companies are all part of the "medical" sector.
Enzo Biochem (NYSE:ENZ) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
Personalis has a consensus target price of $5.50, indicating a potential upside of 347.15%. Given Personalis' higher probable upside, analysts clearly believe Personalis is more favorable than Enzo Biochem.
In the previous week, Enzo Biochem had 1 more articles in the media than Personalis. MarketBeat recorded 2 mentions for Enzo Biochem and 1 mentions for Personalis. Enzo Biochem's average media sentiment score of 0.24 beat Personalis' score of 0.00 indicating that Enzo Biochem is being referred to more favorably in the media.
Enzo Biochem has higher earnings, but lower revenue than Personalis.
Enzo Biochem has a net margin of 99.28% compared to Personalis' net margin of -147.38%. Enzo Biochem's return on equity of -36.71% beat Personalis' return on equity.
36.9% of Enzo Biochem shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 15.5% of Enzo Biochem shares are held by company insiders. Comparatively, 4.1% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Enzo Biochem has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Personalis has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Enzo Biochem received 104 more outperform votes than Personalis when rated by MarketBeat users. However, 65.06% of users gave Personalis an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Summary
Enzo Biochem beats Personalis on 9 of the 15 factors compared between the two stocks.
Get Enzo Biochem News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enzo Biochem Competitors List
Related Companies and Tools
